Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 150 results
A minimalist representation of AI diagnostics and image management in digital pathology.

May 8, 2026

Roche: Up To $1.05 Billion PathAI Acquisition Expands AI-Powered Digital Pathology Platform

Roche has announced a strategic acquisition of PathAI, a digital pathology and AI diagnostics company, valued at up to $1.05 billion. This agreement includes an upfront payment of $750 million, with an additional $300 million contingent on achieving specific milestones. The deal is anticipated to finalize in the latter half of the year, pending regulatory approvals.This acquisition significantly enhances Roche's capabilities in digital pathology and AI diagnostics by integrating PathAI’s advance
A minimalist illustration of a microscope against a dark background, symbolizing diagnostics.

May 7, 2026

Roche’s $750 million PathAI deal shows diagnostics is the most credible near-term exit for vertical AI

Roche's acquisition of PathAI for $750 million marks a significant shift in the pharmaceutical industry's approach to AI, emphasizing diagnostics over speculative drug discovery.Roche's agreement to fully acquire PathAI, a Boston-based AI digital pathology firm, signifies a strategic pivot in big pharma's AI acquisition strategy. The deal, valued at $750 million upfront with potential additional payments tied to regulatory milestones, transitions a five-year partnership into complete ownership,
A minimalist representation of veterinary radiology equipment and an animal silhouette.

May 7, 2026

Travv raises $1.6M for AI veterinary diagnostics platform

Travv has successfully secured $1.6 million in seed funding to enhance its AI-driven veterinary diagnostic platform.The funding round, led by Digitalis Ventures with participation from AniVC, aims to bolster the company's efforts in product development, onboarding veterinary hospitals, and expanding its commercial reach. Travv's primary focus is currently on optimizing radiology workflows; however, it plans to broaden its services to include a wider range of AI-enabled diagnostic tools in the fu
A minimalist illustration of a cancer cell and AI algorithm for cancer diagnostics.

May 7, 2026

Roche Holding AG (RHHBY) Stock Climbs on $750M PathAI Deal to Advance AI-Driven Cancer Diagnostics

Roche Holding AG (RHHBY) has announced a significant acquisition of PathAI for up to $1.05 billion, which is expected to enhance its AI-driven cancer diagnostics capabilities.The acquisition, which includes an initial payment of $750 million and potential milestone payments of $300 million, is set to finalize later this year, pending regulatory approvals. Roche aims to integrate PathAI’s advanced digital pathology technologies into its existing diagnostics framework, enhancing operational effici
A minimalist representation of a pathology slide with an AI overlay in a dark color scheme.

May 7, 2026

Roche buys AI-powered diagnostics player PathAI

Roche has announced its acquisition of PathAI, a prominent player in AI-driven diagnostics, for $1.05 billion, enhancing their longstanding partnership.This acquisition follows a successful collaboration that began five years ago, focusing on integrating PathAI's advanced image analysis algorithms with Roche's Navify digital pathology platform. Since 2021, they have worked on the Image Management System (IMS) platform, which aims to streamline pathology workflows by incorporating AI-enabled comp
A minimalist illustration of a pathology slide and magnifying glass in a dark color scheme.

May 7, 2026

Roche’s $750M PathAI deal aims to bring faster pathology results

Roche is set to acquire PathAI for $750 million, aiming to enhance AI-driven diagnostics in pathology.Roche has announced a definitive agreement to acquire PathAI, a leader in digital pathology and AI technology, to bolster its digital pathology capabilities. This merger is expected to streamline laboratory workflows by integrating PathAI's advanced Image Management System (IMS) with Roche's existing diagnostic tools. The collaboration aims to improve the speed and accuracy of pathology results,
A minimalist representation of AI diagnostics with a computer chip and a line graph.

May 7, 2026

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

Roche has announced a definitive merger agreement to acquire PathAI, aiming to enhance AI-driven diagnostics in pathology. This strategic acquisition marks a significant evolution in Roche's commitment to digital pathology and AI technologies. PathAI, known for its innovative solutions in pathology laboratories and the biopharma sector, has been a partner of Roche since 2021. Their collaboration has intensified over the years, particularly with the development of AI-enabled companion diagnostic
A stained tissue sample on a microscope slide in a lab setting.

May 6, 2026

Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program

Waiv, previously known as Owkin Dx, has announced a strategic collaboration with Daiichi Sankyo to enhance biomarker discovery for antibody-drug conjugate (ADC) programs through digital pathology and AI methodologies.This partnership aims to leverage Waiv's advanced computational pathology platform, which integrates foundation models and AI techniques to analyze early-phase clinical data. The focus will be on tumor microenvironment (TME) analysis using hematoxylin and eosin (H&E) and immunohisto
A blood smear on a microscope slide in a clinical lab setting.

May 6, 2026

Moonlight AI raises $3.3 million to transform hematology labs with AI-powered diagnostics

Moonlight AI, a Swiss startup focused on enhancing hematology diagnostics, has successfully secured $3.3 million in a Seed funding round. This investment aims to leverage AI-driven image analysis to improve the diagnostic processes for cancer patients.The startup's technology utilizes computer vision to analyze routine blood and cytology images, identifying genomic biomarkers and complex disease signatures without the need for costly genomic sequencing. This approach not only streamlines the dia
A flat design illustration of a breast silhouette with a highlighted HER2 biomarker.

May 6, 2026

AI-Powered Breast Cancer Diagnostics Launched in Lithuania

Lithuania has made strides in breast cancer diagnostics with the introduction of an AI tool to assess the HER2 biomarker, marking a significant advancement in oncology within the Baltic region.The National Pathology Center (VPC), part of Vilnius University Hospital Santaros Klinikos, is now utilizing the “Ibex Breast HER2” algorithm, the first CE-IVDR certified AI tool of its kind in the area. This technology aims to enhance treatment accuracy for the over 22,000 women living with breast cancer
A minimalist representation of an eye with a retina, emphasizing retinal analysis.

May 6, 2026

Mediwhale wins EU CE MDR approval for retinal AI cardiovascular risk tool

Mediwhale has announced that its retinal AI tool, Dr. Noon, has received CE MDR certification, allowing it to be marketed across the European Union.This certification aligns with the EU's Medical Device Regulation, which was established to enhance product safety and effectiveness in the medical device sector. Dr. Noon leverages AI to analyze retinal images, aiding in the diagnosis of eye diseases while also predicting cardiovascular risks with a level of precision comparable to cardiac CT scans.
A healthcare professional examining a skin lesion in a dimly lit room.

May 6, 2026

Bradford Teaching Hospitals uses AI to detect skin cancer faster

Bradford Teaching Hospitals NHS Foundation Trust has implemented AI technology to enhance the early detection of skin cancer, aiming to streamline patient care and reduce waiting times.On April 30, 2026, St Luke’s Hospital began utilizing the Deep Ensemble for Recognition of Malignancy (DERM) technology, developed by Skin Analytics. This AI-driven software analyzes skin lesion images to identify potentially cancerous cases swiftly, allowing healthcare professionals to prioritize urgent cases whi